Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 713-716

  Mutimer, David ^a,b   Pillay, Deenan ^a   Cook, Pamela ^a   Ratcliffe, Daina ^a   O'Donnell, Katharina ^b   Dowling, Damien ^b   Shaw, Jean ^a   Elias, Elwyn ^b   Cane, Patricia A ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FAMCICLOVIR; LAMIVUDINE;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; GENE SEQUENCE; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MALE; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS INFECTION; VIRUS LOAD;

2-AMINOPURINE; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0034090544     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315238     Document Type: Article

References (15)

1. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
2. Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
3. Niesters HGM, Hondoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus ADME. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine therapy. J Infect Dis 1998;177:1382-5.
4. Ling R, Mutimer D, Ahmed D, et al. Selection of mutations in the hepatitis B polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
5. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7.
6. Pillay D, Bartholomeusz A, Cane P, et al. Mutations in the hepatitis B DNA polymerase associated with antiviral resistance. Int Antiviral News 1998;6:167-9.
7. Main J, Brown JL, Howells C, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B infection. J Viral Hepat 1996;3:211-5.
8. Korba BE. In vitro evaluation of combination therapies against hepatitis B replication. Antiviral Res 1996;29:49-51.
9. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine combination with penciclovir in vitro. Hepatology 1997;26:216-25.
10. Bartholomeusz A, Schinazi RF, Locarnini S. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepat Rev (in press).
11. Cane P, Mutimer D, Ratcliffe D, et al. Analysis of HBV quasi-species changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Ther 1999;4:7-14.
12. Bartholomeusz A, Locarnini S. Mutations in hepatitis B virus polymerase gene associated with famciclovir and lamivudine resistance. Int Antiviral News 1997;5:123-4.
13. Wolters LMM, Honkoop P, Niesters HGM, de Man RA. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene. J Hepatol 1998;28:909-11.
14. Burroughs NJ, Rand DA, Pillay D, Elias E, Mutimer D. The consequences of quasi-species heterogeneity and within-host ecology for antiviral therapy of hepatitis B virus. In: Therapies for viral hepatitis. London: International Medical Press, 1998:335-43.
15. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998;280:78-86.